CHROMOGRANIN A AND USES THEREOF

摘要

The present invention refers to Chromogranin A (CgA) or a fragment thereof for use in the treatment and/or prevention of cardiotoxicity induced by an anthracycline and to relative pharmaceutical composition. The invention also relates to a method to assess the risk of developing cardiotoxicity induced by an anthracycline.